Pliant Therapeutics Receives FDA Fast Track Designation for PLN-74809 for the Treatment of Idiopathic Pulmonary Fibrosis

Pliant Therapeutics announced that PLN-74809, its oral, dual-selective αvß6/αvß1 integrin inhibitor, has received Fast Track designation from the US FDA for the potential treatment of idiopathic pulmonary fibrosis.